WO2000039136A3 - Human brainiac-5 - Google Patents

Human brainiac-5 Download PDF

Info

Publication number
WO2000039136A3
WO2000039136A3 PCT/US1999/030452 US9930452W WO0039136A3 WO 2000039136 A3 WO2000039136 A3 WO 2000039136A3 US 9930452 W US9930452 W US 9930452W WO 0039136 A3 WO0039136 A3 WO 0039136A3
Authority
WO
WIPO (PCT)
Prior art keywords
brainiac
polypeptides
methods
human
nervous system
Prior art date
Application number
PCT/US1999/030452
Other languages
French (fr)
Other versions
WO2000039136A2 (en
Inventor
Paul E Young
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Paul E Young
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Paul E Young, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP99966502A priority Critical patent/EP1140120A4/en
Priority to AU22021/00A priority patent/AU2202100A/en
Priority to CA002356548A priority patent/CA2356548A1/en
Priority to JP2000591047A priority patent/JP2002533109A/en
Publication of WO2000039136A2 publication Critical patent/WO2000039136A2/en
Publication of WO2000039136A3 publication Critical patent/WO2000039136A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel Brainiac-5 polypeptides which are members of the Brainiac family. In particular, isolated nucleic acid molecules are provided encoding the human Brainiac-5 polypeptides. Brainiac-5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Brainiac-5 activities. Also provided are diagnostic methods for detecting immune and nervous system-related disorders and therapeutic methods for treating, preventing, and/or diagnosing immune and nervous system-related disorders.
PCT/US1999/030452 1998-12-23 1999-12-20 Human brainiac-5 WO2000039136A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99966502A EP1140120A4 (en) 1998-12-23 1999-12-20 Human brainiac-5
AU22021/00A AU2202100A (en) 1998-12-23 1999-12-20 Human brainiac-5
CA002356548A CA2356548A1 (en) 1998-12-23 1999-12-20 Human brainiac-5
JP2000591047A JP2002533109A (en) 1998-12-23 1999-12-20 Human Brainiac-5

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380498P 1998-12-23 1998-12-23
US60/113,804 1998-12-23

Publications (2)

Publication Number Publication Date
WO2000039136A2 WO2000039136A2 (en) 2000-07-06
WO2000039136A3 true WO2000039136A3 (en) 2000-11-02

Family

ID=22351630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030452 WO2000039136A2 (en) 1998-12-23 1999-12-20 Human brainiac-5

Country Status (5)

Country Link
EP (1) EP1140120A4 (en)
JP (1) JP2002533109A (en)
AU (1) AU2202100A (en)
CA (1) CA2356548A1 (en)
WO (1) WO2000039136A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100543857B1 (en) * 1999-09-01 2006-01-23 제넨테크, 인크. Promotion or Inhibition of Angiogenesis and Cardiovascularization
WO2011082345A2 (en) 2009-12-30 2011-07-07 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
CN114933646A (en) * 2022-06-22 2022-08-23 南通市第一老年病医院(上海大学附属南通医院、南通市第六人民医院、南通市肺科医院) SMAGP protein polypeptide construction and application of SMAGP protein polypeptide in anti-fatty liver disease activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021328A2 (en) * 1996-11-13 1998-05-22 Sagami Chemical Research Center Human proteins having transmembrane domains and dnas encoding these proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970214A1 (en) * 1997-03-28 2000-01-12 Human Genome Sciences, Inc. Human muscle derived growth factor - cardiac and pancreatic protein (capp) and gene
CA2314379A1 (en) * 1997-12-18 1999-06-24 Human Genome Sciences, Inc. Human dendriac and brainiac-3
KR100543857B1 (en) * 1999-09-01 2006-01-23 제넨테크, 인크. Promotion or Inhibition of Angiogenesis and Cardiovascularization

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021328A2 (en) * 1996-11-13 1998-05-22 Sagami Chemical Research Center Human proteins having transmembrane domains and dnas encoding these proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 25 July 1995 (1995-07-25), HILLIER ET. AL.: "yn84d06.s1 Soares adult brain N2b5HB55y Homo sapiens cDNA clone" *
DATABASE GENBANK 29 June 1995 (1995-06-29), HILLIER ET. AL.: "yn52d05.a1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone" *
DATABASE GENBANK 8 November 1998 (1998-11-08), LAMERDIN ET. AL.: "Homo sapiens chromosome 19, cosmid F19847, complete sequence" *
See also references of EP1140120A4 *

Also Published As

Publication number Publication date
AU2202100A (en) 2000-07-31
JP2002533109A (en) 2002-10-08
WO2000039136A2 (en) 2000-07-06
EP1140120A4 (en) 2003-05-07
EP1140120A2 (en) 2001-10-10
CA2356548A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
WO1998031806A3 (en) Fc receptors and polypeptides
CA2266439A1 (en) Neutrokine .alpha.
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2001055310A8 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2001055306A8 (en) Nucleic acids, proteins, and antibodies
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
DE69841751D1 (en) Chemokin alpha-5
WO2000039136A3 (en) Human brainiac-5
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2001032128A3 (en) Human chemokine beta-13
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP1712631A3 (en) Fc receptors and polypeptides
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2002074959A3 (en) Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 591047

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2356548

Country of ref document: CA

Ref country code: CA

Ref document number: 2356548

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999966502

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966502

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999966502

Country of ref document: EP